Pronunciation:
soo-kroe-fer-ik ox-ee-hye-drox-ide
Trade Name(s)
Ther. Class.
electrolyte modifiers
Pharm. Class.
phosphate binders
Control of elevated serum phosphorous levels in patients with chronic renal disease currently on dialysis.
Binds dietary phosphorous in the GI tract via ligand exchange.
Therapeutic Effect(s):
Decreased serum phosphorous levels and sequelae of hyperphosphatemia.
Absorption: Phosphate binding is local with no systemic absorption. Minimal amounts of released iron may be absorbed.
Distribution: Unknown.
Metabolism and Excretion: Action is local, no metabolism. Bound phosphate is excreted in feces.
Half-life: Unknown.
TIME/ACTION PROFILE (phosphorous lowering)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | within 4 wk | 12–16 wk | length of treatment |
Contraindicated in:
Use Cautiously in:
GI: discolored feces, diarrhea, nausea, unpleasant taste
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Drug-Drug
PO (Adults) 500 mg 3 times daily (with meals) initially, may be titrated by 500 mg/day at weekly intervals depending on serum phosphorous; usual range is 1500–3000 mg/day in 3 divided doses.
Chewable tablets (wild berry-flavored): 500 mg
Lab Test Considerations: Monitor serum phosphorous levels and dose of sucroferric oxyhydroxide. Dose is titrated in increments of 500 mg (1 tablet) per day as needed until acceptable serum phosphorous level (≤5.5 mg/dL) is reached. Monitor periodically thereafter. May begin titration 1 wk after start of therapy and adjust at weekly intervals.
Decreased serum phosphorous levels.
To view other topics, please sign in or purchase a subscription.
Nursing Central is the award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Complete Product Information.